Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

por ZINNER, RALPH, GRUL, CARLA VISSEREN, SPIGEL, DAVID R., OBASAJU, COLEMAN
Publicado 2015

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

por Naing, Aung, Fu, Siqing, Zinner, Ralph G., Wheler, Jennifer J., Hong, David S., Arakawa, Kazuhito, Falchook, Gerald S., Kurzrock, Razelle
Publicado 2013

Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment

por Myers, Ronald E., Advani, Shailesh M., Myers, Pamela, Selvan, Preethi, Garber, Gregory, Worster, Brooke, Flomenberg, Neal, Chapman, Andrew, Zinner, Ralph
Publicado 2021

Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells

por Naing, Aung, Anderson, Pete, Guma, Sergei, Chien, Hsuan-Chu, McQuinn, Lacey MM, Hein, Joshua P, Zinner, Ralph G, Kleinerman, Eugenie S, Gordon, Nancy
Publicado 2013

Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction

por Huang, Lei, Brunell, David, Stephan, Clifford, Mancuso, James, Yu, Xiaohui, He, Bin, Thompson, Timothy C, Zinner, Ralph, Kim, Jeri, Davies, Peter, Wong, Stephen T C
Publicado 2019

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

por Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S
Publicado 2017

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

por Hou, Ming-Mo, Liu, Xiaochun, Wheler, Jennifer, Naing, Aung, Hong, David, Coleman, Robert L., Tsimberidou, Apostolia, Janku, Filip, Zinner, Ralph, Lu, Karen, Kurzrock, Razelle, Fu, Siqing
Publicado 2014

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

por Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Parkinson, Rose, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S
Publicado 2018

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

por Falchook, Gerald S., Naing, Aung, Wheler, Jennifer J., Tsimberidou, Apostolia M., Zinner, Ralph, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Janku, Filip, Hess, Kenneth R., Bastida, Christel, Kurzrock, Razelle
Publicado 2014

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer

por Falchook, Gerald S., Naing, Aung, Hong, David S., Zinner, Ralph, Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Morgan-Linnell, Sonia K., Jiang, Yunfang, Bastida, Christel, Wheler, Jennifer J., Kurzrock, Razelle
Publicado 2013

A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)

por Bepler, Gerold, Zinner, Ralph G, Moon, James, Calhoun, Royce, Kernstine, Kemp, Williams, Charles C, Mack, Philip C, Oliveira, Vasco, Zheng, Zhong, Stella, Philip J, Redman, Mary W, Gandara, David R
Publicado 2014

S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer

por Shen, Hua, Wang, Gao-Chan, Li, Xiang, Ge, Xin, Wang, Meng, Shi, Zhu-Mei, Bhardwaj, Vikas, Wang, Zi-Xuan, Zinner, Ralph G., Peiper, Stephen C., Aplin, Andrew E., Jiang, Bing-Hua, He, Jun
Publicado 2020

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors

por Jardim, Denis L., Wheler, Jennifer J., Hess, Kenneth, Tsimberidou, Apostolia M., Zinner, Ralph, Janku, Filip, Subbiah, Vivek, Naing, Aung, Piha-Paul, Sarina A., Westin, Shannon N., Roy-Chowdhuri, Sinchita, Meric-Bernstam, Funda, Hong, David S.
Publicado 2014

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

por Wheler, Jennifer J., Moulder, Stacy L., Naing, Aung, Janku, Filip, Piha-Paul, Sarina A., Falchook, Gerald S., Zinner, Ralph, Tsimberidou, Apostolia M., Fu, Siqing, Hong, David S., Atkins, Johnique T., Yelensky, Roman, Stephens, Philip J., Kurzrock, Razelle
Publicado 2014

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

por Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R., Glisson, Bonnie S., Kies, Merrill S., Tsimberidou, Apostolia M., Wheler, Jennifer J., Zinner, Ralph G., Hong, David S., Kurzrock, Razelle, Piha-Paul, Sarina A.
Publicado 2016

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience

por Fu, Siqing, Shi, Naiyi, Wheler, Jennifer, Naing, Aung, Janku, Filip, Piha-Paul, Sarina, Gong, Jing, Hong, David, Tsimberidou, Apostolia, Zinner, Ralph, Subbiah, Vivek, Hou, Ming-Mo, Ramirez, Pedro, Ramondetta, Lois, Lu, Karen, Meric-Bernstam, Funda
Publicado 2015

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors

por Tang, Chad, Fontes Jardim, Denis L., Falchook, Gerald S., Hess, Kenneth, Fu, Siqing, Wheler, Jennifer J., Zinner, Ralph G., Naing, Aung, Tsimberidou, Apostolia M., De Melo Galgiato, Debora, Westin, Shannon N., Meric-Bernstam, Funda, Kurzrock, Razelle, Hong, David S.
Publicado 2013

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

por Tsimberidou, Apostolia M, Said, Rabih, Culotta, Kirk, Wistuba, Ignacio, Jelinek, Jaroslav, Fu, Siqing, Falchook, Gerald, Naing, Aung, Piha-Paul, Sarina, Zinner, Ralph, Siddik, Zahid H, He, Guangan, Hess, Kenneth, Stewart, David J, Kurzrock, Razelle, Issa, Jean-Pierre J
Publicado 2015

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience

por Hou, Ming-Mo, Wang, Zhijie, Janku, Filip, Piha-Paul, Sarina, Naing, Aung, Hong, David, Westin, Shannon, Coleman, Robert L., Sood, Anil K., Tsimberidou, Apostolia M., Subbiah, Vivek, Wheler, Jennifer, Zinner, Ralph, Lu, Karen, Meric-Bernstam, Funda, Fu, Siqing
Publicado 2016

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

por Said, Rabih, Ye, Yang, Falchook, Gerald Steven, Janku, Filip, Naing, Aung, Zinner, Ralph, Blumenschein, George R., Fu, Siqing, Hong, David S., Piha-Paul, Sarina Anne, Wheler, Jennifer J., Kurzrock, Razelle, Palmer, Gary A., Aldape, Kenneth, Hess, Kenneth R., Tsimberidou, Apostolia Maria
Publicado 2014